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Abstract— Samarium-153 (153Sm) are widely used in radia-
tion synovectomy and pain management for patients with bone 
metastases. However, its therapeutic application has not been 
fully explored. 153Sm has been proven to be useful for imaging 
purposes. This provides a beneficial alternative for therapy 
with pure beta emitter especially for liver radioembolization 
with Yttrium-90 (90Y). This study aimed to develop an alterna-
tive radioembolic agent using 153Sm and biocompatible resin 
microparticles for liver cancer therapy. The ion-exchange 
resin; Amberlite IR-120 H+ commercially available in large 
beads were crushed and sieved to 20 – 40 μm and labelled with 
152SmCl3 salt prior to neutron activation. Administered activity 
of 3 GBq 153Sm was aimed based on the standard activity used 
by the 90Y SIR-Spheres. 6 hours irradiation in 1.494 x 1012 
n.cm-2.s-1 flux produced 3.1 GBq.g-1 immediately after activa-
tion. Characterization of the microparticles, gamma spectros-
copy, and in-vitro radiolabelling studies were carried out and 
compared to a commercially available resin readily made in 20 
– 40 μm, Fractogel EMD SO3
- (S). 153Sm-Amberlite micropar-
ticles possess a superior and suitable characteristics for liver 
radioembolization with added imaging capabilities. 
Keywords— Samarium-153 (153Sm), liver cancer, neutron 
activation, radioactive microspheres, radioembolization. 
I. INTRODUCTION  
Liver radioembolization is a non-physiological targeted 
therapy where radiolabeled embolic particles are percutane-
ously delivered directly to the tumour. Liver malignancies 
i.e. hepatocellular carcinoma (HCC) is the third most com-
mon cause of death from cancer worldwide (1). HCC is 
often diagnosed at the later stages when curative approaches 
are no longer feasible (2). Radioembolization using 
90
Y-
microparticles are now increasingly used as palliative 
treatment for HCC. This approach may prolong patients’ 
survival and provide possibilities for curative intents by 
down-staging the tumours for possible resection or trans-
plantation (3-7).  
Currently two commercially available radioembolic 
agents; glass (TheraSphere
®
, Nordion, Canada) and resin 
(SIR-Spheres, SIRTex, Australia) microparticles, both la-
belled with 
90
Y. 
90
Y is produced by high-purity separation 
from Strontium-90 (
90
Sr), which is a nuclear fission product 
of Uranium-235 (
235
U) fuel in a nuclear reactor. The com-
plexity of 
90
Y production resulted in high cost 
90
Y-
microparticles. Since 
90
Y is a pure beta emitter, the distribu-
tion of 
90
Y-microparticles after each procedure is difficult to 
be verified. Technetium-99m macro-aggregated albumin 
(
99m
Tc-MAA) has been used prior to therapy for lung shunt-
ing quantification providing brief information of source 
distribution within the liver and lungs. However, this pre-
treatment planning method did not accurately reflect the 
intrahepatic distribution of 
90
Y-microparticles. This is due 
to resolution and partitioning dissimilarities between 
99m
Tc 
and 
90
Y images, as a result of different physical characteris-
tics and number of particles infused (8, 9). Bremsstrahlung 
imaging may be used, but with very poor spatial resolution. 
Radionuclides with both therapeutic beta and diagnostic 
range of gamma energies would be ideal for “theranostics” 
(therapy plus diagnostic) treatment. Ideal therapeutic radio-
nuclide has optimum physical half-life, suitable linear ener-
gy transfer (LET) and range in tissue, high ratio of non-
penetrating to penetrating radiation, short lived or stable 
daughter, good and selective concentration with prolonged 
retention in tumour and minimum uptake by normal tissue 
(10). Neutron activation is preferred in radionuclide produc-
tion due to wide availability of reactors and relatively sim-
pler process. 
153
Sm is potentially suitable as alternative to 
90
Y. The imaging properties of 
153
Sm has been proven feasi-
ble in a gastrointestinal scintigraphy by Yeong, Abdullah 
(11). Most important microparticles’ feature is size range of 
20 – 40 µm. Microparticles with resistivity to physical heat 
and body chemicals, near plasma density, biocompatible 
and easily labelled with radionuclides are highly preferred.  
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II. MATERIALS & METHODS 
A. Preparation of 152Sm-labelled microparticles 
A commercially available ion-exchange resin; Amberlite 
IR-120 H
+
 (620 – 830 µm) was obtained from Fluka GmbH 
(Buchs, Switzerland). Samarium (III) chloride hexahydrate 
(
152
SmCl3·6H2O) with assay purity ≥99 % was obtained 
from Aldrich Chemical Co. (Wisconsin, USA). The Amber-
lite IR-120 resin was oven dried at 70
o
C for 12 h. The dried 
resin was ground using a grinding planetary ball mill ma-
chine (XQM-(2-6) L, ChangSha LangFeng Metallic Materi-
al Ltd., China) at 200 rpm for approximately 5 h. The resin 
powder was subsequently sieved using a mechanical sieve 
shaker (AS 200 Analytical Sieve Shaker, Retsch GmbH, 
Haan, Germany) attached with 20 and 40 µm wire mesh 
stainless steel test sieves (Endecotts Ltd., London, UK). 
Another commercial ion-exchange resin, Fractogel EMD 
SO3
-
 (S) (Merck Millipore, Massachusetts, USA) suspended 
in 20 % ethanol and 150 mmol.l
-1
 NaCl, ready made in 20 – 
40 µm was used for functional comparison. Using Büchner 
funnel filtration, Fractogel resin was thoroughly washed 
with distilled water to eliminate the ethanol and NaCl. 1 g 
of SmCl3.6H2O was dissolved in 10 ml distilled water. 5 g 
of washed Fractogel resin was poured into the SmCl3 solu-
tion and stirred for 5 min to allow binding of the Sm
3+
 ions 
to the resin. The 
152
Sm-Fractogel resin was washed by 
flushing distilled water through the resin to remove un-
bound Sm
3+
 ions. These steps were repeated for 
152
Sm-
Amberlite resin. Finally, both formulations were oven dried 
at 70
o
C for 12 h.  
B. Characterisation of 152Sm- microparticles  
Fourier transform infrared (FTIR) spectroscopy (600 – 
4000 cm
-1
 range) was carried out (Nicolet 6700, Thermo 
Fisher Scientific Inc., Massachusetts, USA) on the Amber-
lite resin. FTIR spectra of SmCl3 salt, fresh Amberlite resin 
beads, resin after grinding and sieving, resin after labelling, 
and resin after 6 h neutron activation were compared. Field 
emission scanning electron microscopy (FESEM) and ener-
gy dispersive X-ray (EDX) spectroscopy were carried out 
on both 
152
Sm-resins using a FESEM system (Quanta FEG 
250, FEI, Oregon, USA). The particle density, ρs of both 
152
Sm-microparticles were measured using a helium gas 
pycnometer (AccuPvc II 1340, Micromeritics Ins. Corp., 
Georgia, USA) at standard room temperature of 25°C. The 
ρs was incorporated into following equation to obtain parti-
cle concentration, PC (particles.ml
-1
) for each 
152
Sm-
microparticles in 0.9 % saline solution: 
                       (1) 
where, 
C : mass fraction (% w/w) 
Dp : mean diameter of the particles (cm) 
ρf : density of the solvent (g.cm
-3
) 
ρs : particle density (g.cm
-3
)  
C. Neutron activation 
Both 
152
Sm-microparticles were neutron activated in Ma-
laysian Nuclear Agency (MNA), Selangor, Malaysia. The 
TRIGA PUSPATI Reactor (RTP) (Triga Mark II, General 
Atomics, California, USA) is a pool type with solid en-
riched uranium (20 % weight, 235U). The samples were 
sealed in individual polyethylene vial and placed into poly-
ethylene ampoule. Two neutron activation methods (Table 
1); Pneumatic Transfer System (PTS) and Rotary Specimen 
Rack (RR), were studied to achieve 3 GBq of 
153
Sm. The 
irradiation time, t can be estimated using the formula: 
         At= σact φN(1-e
(-λt)
)              (2) 
where, 
At : activity (Bq) 
σact : thermal neutron activation cross-section (barns) 
φ : neutron flux (n.cm-2.s-1) 
N : number of parent atoms = (m / w) x θ x 6.023 x 1023;   
  m : mass of element in the sample  
  w : atomic weight of element  
  θ : isotopic abundance 
  λ : decay constant (s-1) = 0.693/ t1/2  
  t : irradiation time (s)  
Table 1. Neutron activation protocols to achieve 153Sm activity of 3 GBq. 
Method PTS RR 
Thermal neutron flux, θth 
(n.cm-2.s-1) 
4.813 x 1012 1.494 x 1012 
Irradiation time  5 minutes 6 hours 
Location in the reactor Near to the core Peripheral to the core 
Sample entrance and exit  Automatic Manual 
D. Gamma spectroscopy 
After 48 h of cooling, gamma spectroscopy was carried 
out for each sample to determine presence of long-lived 
radionuclide impurities. Hyper-pure germanium detector 
(Canberra, Meriden, USA) and gamma spectrum analysis 
software (GenieTM 2000 Ver. 3.2, Canberra, Meriden, 
USA) were used. Each sample was counted for 5 min at a 
distance so that detection yield do not exceed 20 %. 
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E. Optimum formulation and radiolabelling efficiency  
1 g of SmCl3.6H2O was labelled to 1, 2, 3, 4, 5, and 6 g 
of each resin to determine optimum formulation with best 
labelling efficiency. All samples were activated via PTS for 
5 min. Each sample was equally separated into three 10 ml 
test tubes followed by addition of 10 ml distilled water. The 
samples were mixed using a roller mixer (Movil-Rod, J.P. 
Selecta, Barcelona, Spain) at 50 rpm for 1 h. Next, the sam-
ples were centrifuged at 1200 rpm for 5 min. 1 ml of super-
natant was pipetted from each tube and transferred into 
gamma assay tubes. These steps were repeated until a total 
of 8 ml supernatants were obtained from each sample within 
48 h. All supernatant samples were assayed using gamma 
scintillation counter (2470 Wizard2, PerkinElmer Inc., Mas-
sachusetts, USA). All steps were repeated in human blood 
plasma. Labelling efficiency of each formulation was calcu-
lated using equation previously used (12):  
Retained activity (%) =  (Asus-Asup)/Asus   x 100 % 
where, 
Asus: Activity of suspension before supernatant extraction 
Asup: Activity of supernatant 
III. RESULTS  
 In Figure 1, the functional groups (1000 – 1200 cm-1) of 
the resin were still present despite harsh physical process 
during sample preparation. No major differences between 
peaks in spectra shown in Figure 1 (b) – (e).  
 
Figure 1. (a) SmCl3.6H2O salt. (b) Fresh Amberlite IR-120 H
+ beads. (c) 
Amberlite IR-120 H+ ground and sieved to size 20 – 40 µm. (d) Amberlite 
microparticles labelled with SmCl3.6H2O salt. (e) 
153Sm-Amberlite micro-
particles after 6 h neutron activation.  
In Figure 2 (a), 
152
Sm-Amberlite microparticles were ob-
served to be irregular in shapes, however the size are in the 
acceptable range of 20 – 40 µm. EDX spectra of both resins 
showed that they comprised mostly of C, O, Sm and S. 
However, for 
152
Sm-Fractogel, Cl was also found present in 
a significant amount (1.66 % atomic). 
(a)   (b)  
Figure 2. FESEM images of (a) 152Sm-Amberlite and (b) 152Sm-Fractogel 
microparticles. 
 The particle density of 
152
Sm-Amberlite and 
152
Sm-
Fractogel is 2.538 ± 0.012 and 2.283 ± 0.002 g.cm
-3
 respec-
tively. These correspond to 27.7 and 30.7 million micropar-
ticles respectively. The specific activity per 1 g of 
153
Sm-
resins immediately after 5 min activation via PTS was 0.148 
± 0.004 GBq. This correspond to only 0.072 GBq after 48 h. 
The specific activity achieved via RR method immediately 
after 6 h activation was 3.104 ± 0.029 GBq. The corre-
sponded activity of 1.513 GBq after 48 h was closer to the 
initial target of 3 GBq. Hence, specific activity per micro-
particle for 
153
Sm-Amberlite and 
153
Sm-Fractogel were 55 
Bq and 49 Bq respectively. 
Figure 3. Percentage retention of 153Sm in both resin suspended in distilled 
water (DW) and blood plasma over 48 h. 
 The most dominant photopeak observed in both sam-
ples was the 103.1 ± 0.2 keV, associated with principle 
gamma energy of 
153
Sm. In the 
153
Sm-Fractogel
 
samples, 
two other peaks were consistently observed; 1368.4 ± 0.2 
and 2753.1 ± 0.2 keV, associated with 
24
Na. No significant 
impurities were observed in 
153
Sm-Amberlite
 
samples. 
153
Sm-Amberlite
 
shows significantly better labelling effi-
ciency with 8.42 ± 0.86 % higher compared to 
153
Sm-
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Fractogel. The optimum formulations determined for both 
153
Sm-Amberlite and 
153
Sm-Fractogel was 1:3 and 1:4 re-
spectively. 
153
Sm-Amberlite showed better retention over 48 
h in both distilled water and blood plasma (Figure 3). 
IV. DISCUSSION  
 Ion exchange resins were chosen due to its relatively 
easy labelling and commercial availability. Resins are gen-
erally chemically inert hence results in minimal radionu-
clide leaching. Due to its insoluble characteristic, it is not 
absorbed by the body thus, are extremely safe to be use in 
medicinal products with limited side effects (13). Amberlite 
IR-120 H
+
 was chosen due to its excellent labelling effi-
ciency as reported in an earlier study (12).  
 Chlorine (Cl) in the Fractogel resin may be activated 
into radioactive chlorine (
38
Cl) during neutron activation. 
The presence of Cl in the Fractogel resin is due to the NaCl 
suspension in its commercial packing. From gamma spec-
troscopy, only 
24
Na we found in the samples because 
38
Cl 
may already been fully decay because of its short half-life. 
However, if the concentration is higher, 
38
Cl may still be 
present. This issue may be overcome with more thorough 
resin washing during preparation. 
  The particle densities of the 
152
Sm-microparticles de-
veloped in this study was in between the density of the 
commercial SIR-Sphere (1.6 g.cm
-3
) and TheraSphere (3.2 
g.cm
-3
) particles. Since 
153
Sm-Amberlite are slightly dense, 
this resulted in lower number of microparticles per gram 
which eventually contribute to higher specific activity per 
microparticles compared to 
153
Sm-Fractogel. 
 Despite being non-spherical as a result of grinding, 
153
Sm-Amberlite possess much better functional quality in 
all aspects compared to 
153
Sm-Fractogel. The labelling effi-
ciency and retention of 
153
Sm-Amberlite showed that shape 
irregularity may not be a huge problem since 
153
Sm are still 
mostly intact and the capacity of binding is significantly 
higher than the other resin. 
 
 
V. CONCLUSION 
 We have prepared 20 – 40 µm microparticles using ion 
exchange resin labelled with 
153
Sm produced via neutron 
activation. It is easy to prepare and does not involve unnec-
essary radiation exposure during the labelling process. Am-
berlite IR-120 resin was chosen rather than Fractogel EMD 
SO
3-
 because of its excellent labelling efficiency with strong 
retention of 
153
Sm tested over 48 h, no radioactive impuri-
ties produced from neutron activation, and lower production 
cost. 
153
Sm-microparticles has the potential to be an optimal 
option as an alternative to 
90
Y-microparticles, with added 
advantage of gamma radiation for imaging of source distri-
bution. Dosimetric studies to estimate total 
153
Sm activity 
needed to deliver equivalent tumour dose and therapeutic 
response from 3 GBq 
90
Y shall be carried out. Further ani-
mal studies for in-vivo distribution, biochemical stability 
and labelling efficacy should also be carried out prior to 
clinical studies. 
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